--- title: "US High Growth Tech Stocks to Watch Now" type: "News" locale: "en" url: "https://longbridge.com/en/news/280513194.md" description: "The US market has seen a 2.3% drop in the last week but remains up 13% over the past year, with earnings expected to grow by 16% annually. Key high growth tech stocks include Protagonist Therapeutics, Everpure, and Clear Secure, all showing strong revenue and earnings growth. Protagonist is expected to transition to profitability with a 40.85% annual profit growth, while Everpure focuses on enhancing AI infrastructure. Clear Secure is innovating in identity verification, with a 12% revenue increase and a 23.7% rise in earnings anticipated. Investors can explore a list of 73 high growth tech stocks for potential opportunities." datetime: "2026-03-25T17:56:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280513194.md) - [en](https://longbridge.com/en/news/280513194.md) - [zh-HK](https://longbridge.com/zh-HK/news/280513194.md) --- # US High Growth Tech Stocks to Watch Now Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability, positioning themselves well amidst fluctuating market conditions. ### Top 10 High Growth Tech Companies In The United States Name Revenue Growth Earnings Growth Growth Rating Marker Therapeutics 61.33% 65.71% ★★★★★★ Palantir Technologies 27.02% 31.25% ★★★★★★ Reddit 22.20% 27.96% ★★★★★★ Sandisk 30.23% 46.19% ★★★★★★ Tenaya Therapeutics 58.52% 60.10% ★★★★★☆ Ondas 35.55% 69.51% ★★★★★☆ Zscaler 15.90% 48.88% ★★★★★☆ Duos Technologies Group 53.76% 155.11% ★★★★★☆ Procore Technologies 12.08% 99.98% ★★★★★☆ KVH Industries 25.44% 135.75% ★★★★★☆ Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. ## Protagonist Therapeutics (PTGX) **Simply Wall St Growth Rating:** ★★★★★☆ **Overview:** Protagonist Therapeutics, Inc. is a discovery and development company based in the United States with a market capitalization of $6.29 billion. **Operations:** Protagonist Therapeutics focuses on biotechnology, generating revenue of $46.02 million from this segment. Protagonist Therapeutics, poised for significant growth, is expected to transition from unprofitability to profitability within three years, with an anticipated annual profit growth of 40.85%. This shift is underscored by a robust revenue increase forecast at 23.6% annually, outpacing the US market's average of 10.4%. Recent FDA nods for rusfertide and ICOTYDE(TM) highlight its innovative edge in addressing complex medical conditions like polycythemia vera and plaque psoriasis, potentially setting new industry standards and bolstering its market position. Despite recent financial setbacks noted in its Q4 earnings report—where a net loss of $44.38 million was recorded—these strategic product advancements could catalyze a turnaround, enhancing its competitive stance in the biotech sector. - Unlock comprehensive insights into our analysis of Protagonist Therapeutics stock in this health report. - Explore historical data to track Protagonist Therapeutics' performance over time in our Past section. PTGX Earnings and Revenue Growth as at Mar 2026 ## Everpure (PSTG) **Simply Wall St Growth Rating:** ★★★★★☆ **Overview:** Everpure, Inc. specializes in data storage and management technologies, products, and services globally with a market capitalization of approximately $21.28 billion. **Operations:** With a revenue of approximately $3.66 billion from its Computer Storage Devices segment, Everpure, Inc. focuses on delivering data storage and management solutions both in the U.S. and internationally. Everpure's recent strategic initiatives underscore its commitment to enhancing AI infrastructure capabilities, crucial for maintaining competitiveness in the tech sector. With a focus on reducing complexity and cost in enterprise AI projects, Everpure introduced Evergreen//One for FlashBlade//EXA and the upcoming beta of Everpure Data Stream. These innovations are designed to streamline data handling from ingestion to inference, significantly accelerating time-to-result by automating data movement. This approach not only simplifies the operational aspect of AI deployments but also ensures high-performance standards are met consistently across large-scale applications, evidenced by FlashBlade//EXA's record-setting benchmark scores in SPECstorage Solution 2020 and MLPerf tests. By aligning with NVIDIA's modular STX reference architecture, Everpure is poised to meet the escalating demands of next-generation AI factories, ensuring that their solutions remain at the forefront of technology advancements while supporting sustainable growth. - Take a closer look at Everpure's potential here in our health report. - Assess Everpure's past performance with our detailed historical performance reports. PSTG Earnings and Revenue Growth as at Mar 2026 ## Clear Secure (YOU) **Simply Wall St Growth Rating:** ★★★★★☆ **Overview:** Clear Secure, Inc. operates a secure identity platform under the CLEAR brand name primarily in the United States, with a market cap of approximately $7.13 billion. **Operations:** The company generates revenue primarily through its Secure Biometric Identity Verification segment, which contributed $900.78 million. Clear Secure, recently enhancing its identity verification solutions, demonstrates robust growth and innovation in high-demand tech sectors. With a 12% annual revenue increase and an anticipated 23.7% rise in earnings, the company's strategic focus is evident. Their recent partnership with Ochsner Health to deploy CLEAR1 across healthcare workflows underscores their commitment to integrating advanced technology seamlessly into everyday operations. This initiative not only boosts security but also streamlines patient and employee access, positioning Clear Secure at the forefront of digital identity solutions in healthcare—a sector ripe for technological disruption. - Click here and access our complete health analysis report to understand the dynamics of Clear Secure. - Understand Clear Secure's track record by examining our Past report. YOU Revenue and Expenses Breakdown as at Mar 2026 ## Where To Now? - Discover the full array of 73 US High Growth Tech and AI Stocks right here. - Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. - Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. ## Ready To Venture Into Other Investment Styles? - Explore high-performing small cap companies that haven't yet garnered significant analyst attention. - Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. - Find companies with promising cash flow potential yet trading below their fair value. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [XHS.US](https://longbridge.com/en/quote/XHS.US.md) - [PSTG.US](https://longbridge.com/en/quote/PSTG.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [DAT.US](https://longbridge.com/en/quote/DAT.US.md) - [XDAT.US](https://longbridge.com/en/quote/XDAT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [DTCR.US](https://longbridge.com/en/quote/DTCR.US.md) - [CLOU.US](https://longbridge.com/en/quote/CLOU.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [YOU.US](https://longbridge.com/en/quote/YOU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [P.US](https://longbridge.com/en/quote/P.US.md) ## Related News & Research - [18:00 ETZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent](https://longbridge.com/en/news/285274912.md) - [Major Investor Makes Bold New Move on Seaport Therapeutics Stock](https://longbridge.com/en/news/285144653.md) - [Stock Index Futures Gain on Tech Boost Ahead of Fed Decision and Big Tech Earnings](https://longbridge.com/en/news/284548318.md) - [NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating](https://longbridge.com/en/news/285267932.md) - [Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial](https://longbridge.com/en/news/285276960.md)